INT61422

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 7.87
Pain Relevance 0.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Egfl7) extracellular space (Egfl7) extracellular region (Egfl7)
Anatomy Link Frequency
blood 1
Egfl7 (Mus musculus)
Pain Link Frequency Relevance Heat
palliative 1 90.20 High High
imagery 4 60.88 Quite High
Inflammation 53 52.64 Quite High
cva 10 39.80 Quite Low
agonist 56 5.00 Very Low Very Low Very Low
aspirin 10 5.00 Very Low Very Low Very Low
Bile 10 5.00 Very Low Very Low Very Low
antagonist 8 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
fibrosis 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 11 98.76 Very High Very High Very High
Apoptosis 161 98.40 Very High Very High Very High
Death 85 98.08 Very High Very High Very High
Colon Cancer 3 98.00 Very High Very High Very High
Myocardial Infarction 154 97.68 Very High Very High Very High
Coronary Artery Disease 241 97.36 Very High Very High Very High
Adenocarcinoma 1 95.44 Very High Very High Very High
Disorder Of Lipid Metabolism 634 94.76 High High
Carcinoma 2 87.60 High High
Coronary Heart Disease 153 86.08 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Increased serum neu protein levels were found in 8 of 22 (36%) patients with colorectal carcinomas and in 2 patients with advanced abdominal adenocarcinoma of unknown primary.
Positive_regulation (Increased) of neu protein associated with adenocarcinoma and colon cancer
1) Confidence 0.12 Published 1996 Journal J. Cancer Res. Clin. Oncol. Section Abstract Doc Link 8576278 Disease Relevance 0.77 Pain Relevance 0.09
RhoA/ROCK pathway mediates statin-dependent enhancement of Smad activation
Positive_regulation (activation) of statin
2) Confidence 0.05 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2597201 Disease Relevance 0.76 Pain Relevance 0
is the mediator of statin-induced CTGF overexpression.
Positive_regulation (mediator) of statin
3) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2597201 Disease Relevance 0.25 Pain Relevance 0
In VSMCs, we have found that preincubation with L-mevalonate and GGPP markedly diminishes statin-induced Smad activation and overexpression of TRII and TGF-?
Positive_regulation (activation) of statin
4) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2597201 Disease Relevance 0.93 Pain Relevance 0.03
In the WOSCOPS trial, for example, less than 40% of patients in the original statin group were on a statin 5 years after the study ended.63 In one series, the greatest decline occurred during the first 6 months, and only 25% of patients maintained an acceptable level of compliance to statins 5 years after initiation of therapy.64
Positive_regulation (acceptable) of statin
5) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952453 Disease Relevance 0.85 Pain Relevance 0
Initiatives like the GTWG are excellent models by which to pattern interventions to enhance statin compliance, especially if such programs are expanded to include the outpatient and general community setting.
Positive_regulation (enhance) of statin
6) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952453 Disease Relevance 0.80 Pain Relevance 0
In the WOSCOPS trial, for example, less than 40% of patients in the original statin group were on a statin 5 years after the study ended.63 In one series, the greatest decline occurred during the first 6 months, and only 25% of patients maintained an acceptable level of compliance to statins 5 years after initiation of therapy.64
Positive_regulation (were) of statin
7) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952453 Disease Relevance 0.76 Pain Relevance 0
In patients with known CHD and ischemic HF, analysis of data from the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) showed that those who used statin ?
Positive_regulation (used) of statin associated with coronary artery disease and myocardial infarction
8) Confidence 0.03 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952453 Disease Relevance 1.47 Pain Relevance 0
While an increase in statin utilization might increase drug-related expenditure in the short term, this is counterbalanced eventually by the expected benefits in terms of mortality and morbidity reduction.
Positive_regulation (increase) of statin
9) Confidence 0.02 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2952453 Disease Relevance 0.33 Pain Relevance 0
The CIMT increased significantly by +0.044 mm in the statin monotherapy (control) group (P < 0.001 versus baseline).
Positive_regulation (increased) of statin
10) Confidence 0.01 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.45 Pain Relevance 0
Once again, the patients in the torcetrapib/atorvastatin group exhibited a 6.6 mmHg elevation in systolic blood pressure compared with a 1.5 mmHg elevation in the statin monotherapy group (P < 0.0001).
Positive_regulation (elevation) of statin in blood
11) Confidence 0.01 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2988622 Disease Relevance 0.44 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox